Dr. Gregory George MD PhD Joins Mesoblast Board: A Strategic Boost for the Biotech Giant

Dr. Gregory George MD PhD, Mesoblast's largest shareholder, has joined the company's Board of Directors, marking a significant strategic move for the global leader in allogeneic cellular medicines for inflammatory diseases. Dr. George's unique operational experience and medical background bring valuable insights and expertise to Mesoblast's Board, further enhancing the company's mission to develop and commercialize innovative cellular therapies.

Dr. George, founder and manager of SurgCenter Development, the largest privately owned ambulatory surgical center company in the United States, brings a wealth of experience in building and managing successful healthcare organizations. His background as a medical scientist, coupled with his operational acumen, will provide tremendous value as Mesoblast transitions to become an efficient commercial organization.

Commenting on his appointment, Dr. George said, "I invested in Mesoblast because of my conviction in the technology, Dr. Itescu’s scientific knowledge, vision, and leadership combined with the ability of mesenchymal stem cells to treat, and possibly cure, a wide array of disease processes. I believe in Mesoblast’s potential to create a paradigm shift in health care by blazing a new path forward and making the impossible possible."

Dr. George's insights into innovative treatments for musculoskeletal diseases, such as arthritis and back pain, can help Mesoblast better understand the market potential and patient outcomes for its own therapies targeting these conditions. This understanding can facilitate the rapid incorporation of Mesoblast's products into commercial offerings, similar to how Dr. George's surgical centers successfully integrated innovative treatments.

Chair Jane Bell welcomed Dr. George to the Board, stating, "Greg brings not only a high conviction in Mesoblast and our therapies but additionally important operational and strategic dimensions to our Board that will facilitate our corporate goal of building a major global commercial biotechnology company."



Mesoblast's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. The company has locations in Australia, the United States, and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).

In conclusion, Dr. Gregory George MD PhD's appointment to Mesoblast's Board of Directors aligns with the company's goal of becoming a major global commercial biotechnology company. His unique operational experience and medical background bring valuable operational and strategic dimensions to the Board, further enhancing Mesoblast's mission to develop and commercialize innovative cellular therapies for inflammatory diseases.